These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 12642304)

  • 41. [Ocular manifestations of Behçet's disease].
    Saadouli D; Lahmar A; Ben Mansour K; El Afrit N; Yahyaoui S; El Afrit MA
    J Fr Ophtalmol; 2021 Feb; 44(2):196-202. PubMed ID: 33380351
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease.
    Krause L; Turnbull JR; Torun N; Pleyer U; Zouboulis CC; Foerster MH
    Adv Exp Med Biol; 2003; 528():511-9. PubMed ID: 12918754
    [No Abstract]   [Full Text] [Related]  

  • 43. Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study.
    Alpsoy E; Durusoy C; Yilmaz E; Ozgurel Y; Ermis O; Yazar S; Basaran E
    Arch Dermatol; 2002 Apr; 138(4):467-71. PubMed ID: 11939808
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MONTHLY INTRAVITREAL INFLIXIMAB IN BEHÇET'S DISEASE ACTIVE POSTERIOR UVEITIS: A Long-Term Safety Study.
    Refaat M; Abdullatif AM; Hamza MM; Macky TA; El-Agha MH; Ragab G; Soliman MM
    Retina; 2021 Aug; 41(8):1739-1747. PubMed ID: 33394998
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pattern and causes of visual loss in Behçet's uveitis: short-term and long-term outcomes.
    Amer R; Alsughayyar W; Almeida D
    Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1423-1432. PubMed ID: 28396946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of infliximab on sight-threatening panuveitis in Behçet's disease.
    Sfikakis PP; Theodossiadis PG; Katsiari CG; Kaklamanis P; Markomichelakis NN
    Lancet; 2001 Jul; 358(9278):295-6. PubMed ID: 11498218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ocular Manifestations in Late Onset Behçet's Disease.
    Saadouli D; Mansour KB; Yahyaoui S; Afrit NE; Lahmar A; Afrit AE
    Curr Aging Sci; 2021; 14(1):56-61. PubMed ID: 31994475
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mesenchymal stem cell therapy unable to rescue the vision from advanced Behcet's disease retinal vasculitis: report of three patients.
    Davatchi F; Nikbin B; Shams H; Sadeghi Abdollahi B; Mohyeddin M; Shahram F
    Int J Rheum Dis; 2013 Apr; 16(2):139-47. PubMed ID: 23773637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease.
    Gueudry J; Wechsler B; Terrada C; Gendron G; Cassoux N; Fardeau C; Lehoang P; Piette JC; Bodaghi B
    Am J Ophthalmol; 2008 Dec; 146(6):837-44.e1. PubMed ID: 19027420
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-Term Efficacy and Safety of Interferon Alpha-2a in the Treatment of Chinese Patients with Behçet's Uveitis Not Responding to Conventional Therapy.
    Yang P; Huang G; Du L; Ye Z; Hu K; Wang C; Qi J; Liang L; Wu L; Cao Q; Kijlstra A
    Ocul Immunol Inflamm; 2019; 27(1):7-14. PubMed ID: 29040035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interferon alfa-2b, colchicine, and benzathine penicillin versus colchicine and benzathine penicillin in Behçet's disease: a randomised trial.
    Demiroglu H; Ozcebe OI; Barista I; Dündar S; Eldem B
    Lancet; 2000 Feb; 355(9204):605-9. PubMed ID: 10696980
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients.
    Lee JH; Lee CS; Lee SC
    BMC Ophthalmol; 2018 Feb; 18(1):52. PubMed ID: 29463220
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study.
    Interlandi E; Leccese P; Olivieri I; Latanza L
    Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S58-62. PubMed ID: 25005224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Results of interferon-alfa therapy in patients with Behçet uveitis.
    Tugal-Tutkun I; Güney-Tefekli E; Urgancioglu M
    Graefes Arch Clin Exp Ophthalmol; 2006 Dec; 244(12):1692-5. PubMed ID: 16673135
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interferon therapy for Behçet's disease.
    Alpsoy E; Yilmaz E; Başaran E
    J Am Acad Dermatol; 1994 Oct; 31(4):617-9. PubMed ID: 8089288
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term effects of interferon alpha 2A treatment in Behçet's disease.
    Boyvat A; Sişman-Solak C; Gürler A
    Dermatology; 2000; 201(1):40-3. PubMed ID: 10971058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Spectrum of Behçet's disease in the Indian population.
    Sachdev N; Kapali N; Singh R; Gupta V; Gupta A
    Int Ophthalmol; 2009 Dec; 29(6):495-501. PubMed ID: 18936879
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-TNF-alpha therapy for sight threatening uveitis.
    Lindstedt EW; Baarsma GS; Kuijpers RW; van Hagen PM
    Br J Ophthalmol; 2005 May; 89(5):533-6. PubMed ID: 15834077
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term therapy with low dose cyclosporin A in ocular Behçet's disease.
    Ozdal PC; Ortaç S; Taskintuna I; Firat E
    Doc Ophthalmol; 2002 Nov; 105(3):301-12. PubMed ID: 12539855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ocular Manifestations, Conventional Fundus Fluorescein Angiographic Findings, and Relationship Between Angiographic Findings and Visual Acuity in Behçet's Disease.
    Bazvand F; Zarei M; Ebrahimiadib N; Karkhaneh R; Davoudi S; Soleimanzadeh M; Sharifian E; Roohipoor R; Modjtahedi BS
    Semin Ophthalmol; 2017; 32(6):764-771. PubMed ID: 27715380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.